Table 1. Geographic origin, type and classification of lesions of clinically suspected and laboratory confirmed BUD patients.
| Region | District | Clinically suspected BUD cases | Laboratory confirmed BUD patientsa | |||||
| Total per districtb | Non-ulcerative lesions | Ulcerative lesions | Category Ic | Category IId | Category IIIe | |||
| Central | Sotouboua | 4.9% (4/82) | 0% (0/64) | 0% (0/64) | 0% (0/64) | 0% (0/64) | 0% (0/64) | 0% (0/64) |
| Maritime | Golfe | 2.4% (2/82) | 1.6% (1/64) | 0% (0/64) | 1.6% (1/64) | 0% (0/64) | 0% (0/64) | 1.6% (1/64) |
| Yoto | 48.8% (40/82) | 57.8% (37/64) | 31.3% (20/64) | 26.6% (17/64) | 32.8% (21/64) | 18.8% (12/64) | 6.3% (4/64) | |
| Vo | 1.2% (1/82) | 1.6% (1/64) | 1.6% (1/64) | 0% (0/64) | 1.6% (1/64) | 0% (0/64) | 0% (0/64) | |
| Zio | 36.6% (30/82) | 34.4% (22/64) | 18.8% (12/64) | 15.6% (10/64) | 9.4% (6/64) | 18.8% (12/64) | 6.3% (4/64) | |
| Plateauxf | Amoú | 1.2% (1/82) | 0% (0/64) | 0% (0/64) | 0% (0/64) | 0% (0/64) | 0% (0/64) | 0% (0/64) |
| Anié | 1.2% (1/82) | 1.6% (1/64) | 0% (0/64) | 1.6% (1/64) | 0% (0/64) | 1.6% (1/64) | 0% (0/64) | |
| Haho | 1.2% (1/82) | 0% (0/64) | 0% (0/64) | 0% (0/64) | 0% (0/64) | 0% (0/64) | 0% (0/64) | |
| Ogou | 1.2% (1/82) | 1.6% (1/64) | 0% (0/64) | 1.6% (1/64) | 0% (0/64) | 0% (0/64) | 1.6% (1/64) | |
| Savanesf | Dapaong | 1.2% (1/82) | 1.6% (1/64) | 0% (0/64) | 1.6% (1/64) | 0% (0/64) | 1.6% (1/64) | 0% (0/64) |
| Total | 100% (82/82) | 100% (64/64) | 51.6% (33/64) | 48.4% (31/64) | 43.8% (28/64) | 40.6% (26/64) | 15.6% (10/64) | |
Table 1 shows the geographic origin of all suspected and confirmed BUD patients, and type/category of lesions of confirmed BUD patients who presented from September 2010 through April 2012 in Togo. More than 85% of confirmed BUD patients originated from the districts Yoto and Zio of region “Maritime”.
Patients were confirmed by dry-reagent-based IS2404, standard gel-based IS2404 PCR and/or IS2404 quantitative real-time PCR. BUD, Buruli ulcer disease.
Number of confirmed BUD patients per district.
Category I, single lesion <50 mm in diameter.
Category II, single lesion between 50 and 150 mm in diameter.
Category III, single lesion >150 mm in diameter or multiple lesions, osteomyelitis or lesions at critical sites.
Laboratory confirmed BUD patients were referred to CHR, Tsévié, for antimycobacterial treatment.